Cinfa reinforces its commitment to global health
accessibility on World
Health Day
(MIDDLE EAST) - On World Health Day,
Cinfa highlights the
importance of promoting
healthy lifestyles to
prevent and manage various
diseases. At the same time,
it remains committed to
developing high-quality,
accessible, and effective
treatments that address key
healthcare challenges
worldwide. To this end, the
company always collaborates
closely with healthcare
professionals to understand
and address patients' real
needs and ensure they have
access to the medicines they
need.
With this
undertaking, Cinfa works to
expand medication coverage
in the Middle East and
address present and future
health challenges, such as
increasing longevity and the
growing prevalence of
chronic conditions, ensuring
that patients receive the
care and treatment they need
at every stage of their
lives. As Franc Vives, Chief
International Officer at
Cinfa Group, highlights: “In
regions like MENA, where
non-communicable diseases
place significant pressure
on families, health systems,
and economies, we are
committed to expanding
access to essential
medicines for every patient,
regardless of geography or
economic status.”
Cinfa is focusing on
research and innovation to
develop and introduce new
products. Specifically, the
company is expanding its
portfolio into new
therapeutic categories where
the company was not
previously present in the
region, including chronic or
non-communicable diseases
with a significant impact in
MENA. Among these,
diabetes—particularly type
2—is a key focus, with
research efforts centred on
DPP-4 and SGLT2 inhibitors.
Dr. Alicia López
de Ocáriz, Corporate Medical
Director of Cinfa,
points out that
“The MENA Region has the
highest regional prevalence
of Diabetes (16.2%)
- a figure expected to rise
significantly in the coming
years. Our commitment is to
provide effective,
affordable treatments that
address this disease and its
associated higher risk of
health problems, including
heart attack, stroke, kidney
failure and vision loss”.
Cinfa is also investing
in cardiovascular and
neurological areas, with
special emphasis on
antithrombotic treatments
for the prevention of stroke
and embolism.
“Through a sustained
investment strategy, we aim
to facilitate access and
availability of our products
across the MENA region by
expanding our development,
production and distribution
capacities and utilizing
Industry 4.0 technologies,
where all processes are
fully integrated,
digitalized, and automated”,
concludes Franc Vives.
